Herbalife Nutrition Ltd. (HLF) Earnings
Herbalife Nutrition Ltd. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $0.59. HLF has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise +4.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.61 | $0.64 | +5.4% | $1.3B | +1.1% |
| Feb 18, 2026 | $0.48 | $0.45 | -6.2% | $1.3B | +3.1% |
| Nov 5, 2025 | $0.47 | $0.50 | +6.4% | $1.3B | +2.0% |
| Aug 6, 2025 | $0.53 | $0.59 | +11.3% | $1.3B | +1.0% |
| Apr 30, 2025 | $0.40 | $0.59 | +47.5% | $1.2B | -0.3% |
| Feb 19, 2025 | $0.10 | $0.36 | +260.0% | $1.2B | +1.1% |
| Oct 30, 2024 | $0.35 | $0.57 | +62.9% | $1.2B | -1.2% |
| Jul 31, 2024 | $0.43 | $0.54 | +25.6% | $1.3B | +3.3% |
| May 1, 2024 | $0.37 | $0.49 | +32.4% | $1.3B | +0.6% |
| Feb 14, 2024 | $0.38 | $0.28 | -26.3% | $1.2B | +2.3% |
| Nov 1, 2023 | $0.75 | $0.65 | -13.3% | $1.3B | +2.3% |
| Aug 2, 2023 | $0.69 | $0.74 | +7.2% | $1.3B | +2.9% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Delivered strong start to 2026 with net sales and adjusted EBITDA exceeding guidance. - Building a more connected, personalized approach to health and wellness. - Completed debt refinancing, expecting ~$45 million annual cash interest savings. - Announced acquisition of Vionic's core personalized nutrition business, with Vionic's products to be offered in Europe in June and U.S. in July. - Rollout of new packaging across global product portfolio beginning in March, expected to be substantially completed by 2027. - Kicked off first Extravaganza events of the year, starting in India, with more events to come in various regions. - Over the past two years, stabilized net sales, returned to growth, expanded adjusted EBITDA margins, strengthened balance sheet, reduced debt, and completed strategic acquisitions.
Guidance
- Second quarter expected net sales: reported 1.5% - 5.5% year-over-year increase, constant currency 1% - 5% year-over-year increase; adjusted EBITDA $150 million - $170 million on both reported and constant currency basis. - Full year expected reported net sales increase 1.5% - 5.5% year-over-year; constant currency net sales increase 1% - 5% year-over-year; adjusted EBITDA $675 million - $705 million on both reported and constant currency basis. - India GST-related net incremental cost expected to be ~$20 million - $25 million headwind to full-year adjusted EBITDA. - Preliminary estimate of impact of higher oil prices. - Capital expenditures expected $50 million - $80 million for full year, capitalized SaaS implementation costs $35 million - $55 million. - Full-year adjusted effective tax rate expected ~30%.
Segment performance
First quarter net sales were $1.3 billion, up 7.8% year-over-year and up 5.4% on a constant currency basis. Adjusted EBITDA was $176 million. India achieved record quarterly net sales for the second consecutive quarter. Regionally, Asia Pacific had 17% year-over-year reported net sales growth, Latin America had 17% year-over-year reported net sales growth, EMEA had 1% year-over-year reported net sales growth, North America had 3% year-over-year net sales decline, and China had 12% year-over-year reported net sales decline. Revenue contribution: India's net sales were a significant part, with record sales in Q1.
Analyst Q&A
Q: About Protocol, could you discuss behaviors seen from U.S. beta group and how they are shaping up?
A: Beta phase continues, getting feedback, enlarged beta phase as more countries are included, Protocol is an end-to-end solution not yet rolled into forecast.
Q: On India, how has thinking evolved on potential price reduction programs in other markets and guidance for India constant currency?
A: India had strong growth due to GST reduction, momentum expected to continue, running tests based on India results for other markets.
Q: On higher oil costs, how flowing through to consumer?
A: Not flowing through, absorbing it for rest of year.
Q: On China, how to think about it and its percentage of sales?
A: China is under 5% of sales, work in progress, strategies being implemented.
Q: On Protocol launch in nutrition clubs and packaging redesign feedback?
A: Early in nutrition clubs, packaging redesign initial feedback positive from research.
Q: On transition of preferred members to new e-commerce platform and interaction with Protocol?
A: Very early, uptake on subscriptions for preferred customers is positive.
Q: On personalized nutrition segmentation and distributor feedback?
A: Vionic acquisition helps hit different price points, personalized nutrition is part of strategy.
Q: On EMEA direct selling market softness?
A: Markets evolving, offer needs to evolve with technology.
Q: On U.S. market participation in diabetes prevention program?
A: Pilot, not having material impact.
Q: On Vionic products in Europe and U.S., product offerings, rebranding, Link Biosciences product timeline, and capital allocation priorities post debt refinancing?
A: Vionic products essentially same in both markets, Link Biosciences product out in Q1 next year, four acquisitions connected, capital allocation priority still to get gross debt down to $1.4 billion by 2028.